S1PR1 and colitis: The daily oral administration of etrasimod (S1PR1/R4/R5 modulator) alleviates the colonic inflammatory response by downregulating the expression of T cell and monocyte markers in a cluster of differentiated CD4+CD45RBhigh T cell transfer mouse model of colitis (15).